Table 3.

Distribution of Independent Variables in Patients Within Different Quartiles of 0- to 24-Hour Area Under the Curve/Minimum Inhibitory Concentration (AUC_0-24)

Covariate	Quartile 1	Quartile 2	Quartile 3	Quartile 4	P Value
Isoniazid	0–116	>116–189.5	>189.5–355.8	>355.8
Median age, y	32.6	31.1	32.3	33.7	.95
% Re-treatment	36	44	40	36	.92
% Side effects	24	32	20	64	.004
% Extensive radiological disease	64	88	64	68	.19
% Cavities	44	60	44	60	.46
% Smear 3+	28	24	20	24	.93
Median TTD	10	9	11	11	.94
% Poor adherence	4	16	4	16	.26
Median log10 VL	4.8	4.5	3.4	5.16	.22
Median log10 CD4	2.1	2.3	2.5	2.4	.68
Rifampicin	0–184	>184–299	>299–560	>560
Median age, y	32.6	32.6	32.4	33.7	.68
% Re-treatment	40	44	32	40	.85
% Side effects	32	28	32	48	.46
% Extensive radiological disease	64	60	84	76	.22
% Cavities	44	48	60	56	.66
% Smear 3+	16	12	28	40	.09
Median TTD	11	13	10	9	.20
% Poor adherence	8	4	12	16	.53
Median log10 VL	4.6	4.7	4.5	5.2	.22
Median log10 CD4	2.1	2.3	2.5	2.4	.32
Pyrazinamide	0–10	>10–13.7	>13.7–19.8	>19.8
Median age, y	31.15	32.47	34.8	33.1	.75
% Re-treatment	48	36	28	44	.48
% Side effects	28	44	48	20	.12
% Extensive radiological disease	72	88	68	56	.09
% Cavities	40	68	60	40	.11
% Smear 3+	20	24	24	28	.93
Median TTD	11	8	9	11	.87
% Poor adherence	12	8	12	8	.93
Median log10 VL	4.9	4.8	4.8	4.1	.88
Median log10 CD4	2.5	2.5	2.3	2.2	.13

The significance for bold values are P < .05. Abbreviations: TTD, time to culture positivity at baseline; VL, viral load.